Literature DB >> 1789130

Whole body capillary exchange of albumin.

L Bent-Hansen1.   

Abstract

Analyzed versus the large plasma marker of fibrinogen, initial albumin plasma disappearance in man or animals is sharply biphasic. Albumin uptake in skin, muscle and viscera follow the same pattern, suggesting serial barriers to albumin efflux in these tissues, i.e., a capillary membrane barrier and an interstitial barrier. The transport across the membrane is rapid, in both directions and probably mediated by diffusion, while interstitial transport may be slow, mainly unilateral and mainly convective. This implies the interstitial barrier and not the capillary membrane to be the rate limiting step of total plasma to lymph albumin transport. The distribution of efflux indicates whole body plasma disappearance to reflect mainly the uptake in muscle, lung, skin, and gut, while the highly perfused tissues of heart, kidney and sinusoid tissue have smaller influence due to their lower body masses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1789130

Source DB:  PubMed          Journal:  Acta Physiol Scand Suppl        ISSN: 0302-2994


  5 in total

1.  Discrepancies in pharmacokinetic parameter estimation between bolus and infusion studies in the perfused rat hindlimb.

Authors:  A C Heatherington; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1995-10

2.  Plasmonic Paper Microneedle Patch for On-Patch Detection of Molecules in Dermal Interstitial Fluid.

Authors:  Chandana Kolluru; Rohit Gupta; Qisheng Jiang; Mikayla Williams; Hamed Gholami Derami; Sisi Cao; Richard K Noel; Srikanth Singamaneni; Mark R Prausnitz
Journal:  ACS Sens       Date:  2019-05-22       Impact factor: 7.711

3.  Fast versus slow infusion of 20% albumin: a randomized controlled cross-over trial in volunteers.

Authors:  Markus Zdolsek; Folke Sjöberg; Robert G Hahn
Journal:  Intensive Care Med Exp       Date:  2022-07-18

4.  Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats.

Authors:  M S Huijberts; B H Wolffenbuttel; F R Crijns; A C Nieuwenhuijzen Kruseman; M H Bemelmans; H A Struijker Boudier
Journal:  Diabetologia       Date:  1994-01       Impact factor: 10.122

5.  Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice.

Authors:  Cheryl A Stoddart; Geneviève Nault; Sofiya A Galkina; Karen Thibaudeau; Peter Bakis; Nathalie Bousquet-Gagnon; Martin Robitaille; Maryanne Bellomo; Véronique Paradis; Patricia Liscourt; Alexandra Lobach; Marie-Eve Rivard; Roger G Ptak; Marie K Mankowski; Dominique Bridon; Omar Quraishi
Journal:  J Biol Chem       Date:  2008-09-22       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.